Pharmacological Modulation of Cocaine Effects - 1

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Johns Hopkins University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000201

Purpose

The purpose of this study is to conduct human laboratory studies of possible cocaine interactions with various potential treatment medications.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Selegiline	Phase II

Drug Information available for: Selegiline 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Selegiline hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Pharmacological Modulation of Cocaine Effects

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment:	0
Estimated Study Completion Date:	December 2001

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000201

Locations

United States, Maryland
Johns Hopkins University (BPRU) Bayview Campus
Baltimore, Maryland, United States, 21224 6823

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Johns Hopkins University

Investigators

Principal Investigator:

George Bigelow, Ph.D.

Johns Hopkins University

More Information

Study ID Numbers:	NIDA-05196-1, R01-05196-1
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000201
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Cocaine-Related Disorders
Selegiline
Mental Disorders

Substance-Related Disorders
Disorders of Environmental Origin
Cocaine

Additional relevant MeSH terms:

Molecular Mechanisms of Pharmacological Action
Anti-Dyskinesia Agents
Therapeutic Uses
Physiological Effects of Drugs
Monoamine Oxidase Inhibitors
Antiparkinson Agents

Enzyme Inhibitors
Central Nervous System Agents
Protective Agents
Neuroprotective Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009